CD274 and cancer: Given that the cell surface PD-L1 expressed on cancer cells mainly dominates the anticancer immunosuppression [24], we determined whether the cell surface PD-L1 was increased after MLN4924 treatment, using the fluorescence-labeled anti-PD-L1 antibody for FACS analysis.